412 related articles for article (PubMed ID: 26762977)
1. Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations.
Maggio I; Stefanucci L; Janssen JM; Liu J; Chen X; Mouly V; Gonçalves MA
Nucleic Acids Res; 2016 Feb; 44(3):1449-70. PubMed ID: 26762977
[TBL] [Abstract][Full Text] [Related]
2. Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.
Maggio I; Liu J; Janssen JM; Chen X; Gonçalves MA
Sci Rep; 2016 Nov; 6():37051. PubMed ID: 27845387
[TBL] [Abstract][Full Text] [Related]
3. High-Capacity Adenoviral Vectors Permit Robust and Versatile Testing of
Brescia M; Janssen JM; Liu J; Gonçalves MAFV
Cells; 2020 Apr; 9(4):. PubMed ID: 32252479
[TBL] [Abstract][Full Text] [Related]
4. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.
Ifuku M; Iwabuchi KA; Tanaka M; Lung MSY; Hotta A
Methods Mol Biol; 2018; 1828():191-217. PubMed ID: 30171543
[TBL] [Abstract][Full Text] [Related]
5. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients.
Ousterout DG; Perez-Pinera P; Thakore PI; Kabadi AM; Brown MT; Qin X; Fedrigo O; Mouly V; Tremblay JP; Gersbach CA
Mol Ther; 2013 Sep; 21(9):1718-26. PubMed ID: 23732986
[TBL] [Abstract][Full Text] [Related]
6. Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy.
Mata López S; Balog-Alvarez C; Vitha S; Bettis AK; Canessa EH; Kornegay JN; Nghiem PP
PLoS One; 2020; 15(1):e0228072. PubMed ID: 31961902
[TBL] [Abstract][Full Text] [Related]
7. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
8. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.
Ousterout DG; Kabadi AM; Thakore PI; Perez-Pinera P; Brown MT; Majoros WH; Reddy TE; Gersbach CA
Mol Ther; 2015 Mar; 23(3):523-32. PubMed ID: 25492562
[TBL] [Abstract][Full Text] [Related]
9. Transiently expressed CRISPR/Cas9 induces wild-type dystrophin in vitro in DMD patient myoblasts carrying duplications.
Pini V; Mariot V; Dumonceaux J; Counsell J; O'Neill HC; Farmer S; Conti F; Muntoni F
Sci Rep; 2022 Mar; 12(1):3756. PubMed ID: 35260651
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of viral vectors as vehicles for DMD gene editing.
Maggio I; Chen X; Gonçalves MA
Genome Med; 2016 May; 8(1):59. PubMed ID: 27215286
[TBL] [Abstract][Full Text] [Related]
11. Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in.
Popplewell L; Koo T; Leclerc X; Duclert A; Mamchaoui K; Gouble A; Mouly V; Voit T; Pâques F; Cédrone F; Isman O; Yáñez-Muñoz RJ; Dickson G
Hum Gene Ther; 2013 Jul; 24(7):692-701. PubMed ID: 23790397
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
[TBL] [Abstract][Full Text] [Related]
13. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.
Bengtsson NE; Hall JK; Odom GL; Phelps MP; Andrus CR; Hawkins RD; Hauschka SD; Chamberlain JR; Chamberlain JS
Nat Commun; 2017 Feb; 8():14454. PubMed ID: 28195574
[TBL] [Abstract][Full Text] [Related]
14. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
[TBL] [Abstract][Full Text] [Related]
15. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy.
Moretti A; Fonteyne L; Giesert F; Hoppmann P; Meier AB; Bozoglu T; Baehr A; Schneider CM; Sinnecker D; Klett K; Fröhlich T; Rahman FA; Haufe T; Sun S; Jurisch V; Kessler B; Hinkel R; Dirschinger R; Martens E; Jilek C; Graf A; Krebs S; Santamaria G; Kurome M; Zakhartchenko V; Campbell B; Voelse K; Wolf A; Ziegler T; Reichert S; Lee S; Flenkenthaler F; Dorn T; Jeremias I; Blum H; Dendorfer A; Schnieke A; Krause S; Walter MC; Klymiuk N; Laugwitz KL; Wolf E; Wurst W; Kupatt C
Nat Med; 2020 Feb; 26(2):207-214. PubMed ID: 31988462
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
Wong TWY; Cohn RD
Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
[TBL] [Abstract][Full Text] [Related]
17. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
[TBL] [Abstract][Full Text] [Related]
18. In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers.
Chen M; Shi H; Gou S; Wang X; Li L; Jin Q; Wu H; Zhang H; Li Y; Wang L; Li H; Lin J; Guo W; Jiang Z; Yang X; Xu A; Zhu Y; Zhang C; Lai L; Li X
Genome Med; 2021 Apr; 13(1):57. PubMed ID: 33845891
[TBL] [Abstract][Full Text] [Related]
19. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
[TBL] [Abstract][Full Text] [Related]
20. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A
Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
